

Outlook Therapeutics, Inc. Logo

## Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

October 5, 2021

**Outlook Therapeutics senior leadership team to provide a company overview and participate on industry panel on Thursday, October 7, 2021**

ISELIN, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- [Outlook Therapeutics, Inc.](#) (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that [C. Russell Trenary, President and Chief Executive Officer](#) of Outlook Therapeutics, will make a company presentation at the OIS Retina Innovation Showcase and [Jeff Evanson, Chief Commercial Officer](#), will participate in an industry panel on Thursday, October 7, 2021 in San Antonio, Texas and virtually.

Details for the presentations are as follows:

### **Innovation Showcase: Company Presentation**

C. Russell Trenary III, President & Chief Executive Officer  
Thursday, October 7, 2021 at 8:55 AM CT

### **Retina Industry Insights Panel**

Jeff Evanson, Chief Commercial Officer  
Thursday, October 7, 2021 at 4:35 PM CT

For more information and to register for this event, please visit [OIS\\_Retina@ASRS](mailto:OIS_Retina@ASRS).

### **About the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase**

Launched in 2009, the Ophthalmology Innovation Summit serves to showcase novel therapies in development for unmet needs in ophthalmic disease and vision disorders, bringing together entrepreneurs, ophthalmic start-up companies, clinical thought leaders, industry executives and investment professionals to facilitate an exchange of information and connections to drive innovation in the retina, anterior segment, and optometry.

### **About Outlook Therapeutics, Inc.**

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit [www.outlooktherapeutics.com](http://www.outlooktherapeutics.com).

### **CONTACTS:**

#### **Media Inquiries:**

Harriet Ullman  
Vice President  
LaVoie Health Science  
T: 617-669-3082  
[hullman@lavoiehealthscience.com](mailto:hullman@lavoiehealthscience.com)

#### **Investor Inquiries:**

Jenene Thomas  
Chief Executive Officer  
JTC Team, LLC  
T: 833.475.8247  
[OTLK@jtcir.com](mailto:OTLK@jtcir.com)



Source: Outlook Therapeutics, Inc.